| Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes A Nazha, M Narkhede, T Radivoyevitch, DJ Seastone, BJ Patel, AT Gerds, ... Leukemia 30 (11), 2214-2220, 2016 | 170 | 2016 |
| NCCN guidelines® insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JE Chang, B Christian, JS Abramson, RH Advani, ... Journal of the National Comprehensive Cancer Network 19 (11), 1218-1230, 2021 | 112 | 2021 |
| Primary effusion lymphoma: current perspectives M Narkhede, S Arora, C Ujjani OncoTargets and therapy, 3747-3754, 2018 | 77 | 2018 |
| Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients MR Wilson, TA Eyre, AA Kirkwood, N Wong Doo, C Soussain, S Choquet, ... Blood, The Journal of the American Society of Hematology 139 (16), 2499-2511, 2022 | 53 | 2022 |
| Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia LE Roeker, MS Yazdy, J Rhodes, J Goodfriend, M Narkhede, J Carver, ... JAMA network open 2 (12), e1916326-e1916326, 2019 | 27 | 2019 |
| Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis S Sidana, M Narkhede, P Elson, D Hastings, B Faiman, J Valent, ... PLoS One 12 (3), e0172996, 2017 | 22 | 2017 |
| NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines AD Zelenetz, LI Gordon, JS Abramson, RH Advani, B Andreadis, ... Journal of the National Comprehensive Cancer Network 21 (11), 1118-1131, 2023 | 14 | 2023 |
| Copanlisib in the treatment of non-Hodgkin lymphoma M Narkhede, BD Cheson Future Oncology 16 (26), 1947-1955, 2020 | 14 | 2020 |
| Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma M Narkhede, G Goyal, L Shea, A Mehta, S Giri Blood Advances 6 (14), 4122-4131, 2022 | 13 | 2022 |
| The association of histologic grade with acute graft‐versus‐host disease response and outcomes M Narkhede, L Rybicki, D Abounader, B Bolwell, R Dean, AT Gerds, ... American Journal of Hematology 92 (7), 683-688, 2017 | 12 | 2017 |
| No difference in overall survival between R-CHOP and R-EPOCH among patients with advanced stage MYC-rearranged, double hit, or triple hit diffuse large B-cell lymphoma T Magnusson, M Narkhede, A Mehta, G Goyal EHA 2021 virtual congress, 9-17, 2021 | 11 | 2021 |
| Subcutaneous epcoritamab in combination with rituximab+ lenalidomide (R2) for first-line treatment of follicular lymphoma: initial results from Phase 1/2 Trial L Falchi, LA Leslie, D Belada, K Kopeckova, F Offner, J Brody, M Canales, ... Blood 140 (Supplement 1), 1471-1473, 2022 | 9 | 2022 |
| Subcutaneous epcoritamab in combination with R-CHOP in patients with previously untreated high-risk diffuse large B-cell lymphoma: preliminary results from a phase 1/2 trial D Belada, JH Christensen, K Drott, S Snauwaert, J Brody, M Narkhede, ... Blood 138, 1413, 2021 | 9 | 2021 |
| Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit/frail patients with previously untreated diffuse large B-cell lymphoma AJ Olszewski, H Eradat, A Avigdor, NA Horowitz, S Babu, I Levi, ... Blood 142, 855, 2023 | 6 | 2023 |
| Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the … G Goyal, T Magnusson, X Wang, J Roose, M Narkhede, E Seymour Haematologica 108 (4), 1190, 2023 | 5 | 2023 |
| The Revised International Prognostic Scoring System" Molecular"(IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS) A Nazha, MS Narkhede, T Radivoyevitch, M Kalaycio, BJ Patel, AT Gerds, ... Blood 126 (23), 607, 2015 | 5 | 2015 |
| Interim analysis of investigator-initiated phase 2 trial of siltuximab in treatment of cytokine release syndrome and immune effector cell associated neurotoxicity related to … M Narkhede, A Di Stasi, S Bal, LK Shea, G Goyal, A Sledge, P Hardwick, ... 2023 tandem meetings| transplantation & cellular therapy meetings of ASTCT …, 2023 | 4 | 2023 |
| Economic burden of hematopoietic cell transplantation (HCT) among commercially insured patients with hematological malignancies in the United States (US) M Narkhede, N Liu, A Surinach, MA Fanale, KS Yu, A Winter Blood 140 (Supplement 1), 10798-10800, 2022 | 4 | 2022 |
| CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges M Narkhede, A Mehta, SM Ansell, G Goyal Annals of Translational Medicine 9 (12), 2021 | 4 | 2021 |
| External validation and revision of thrombosis lymphoma/throly/score D Antic, N Milic, B Mihaljevic, B Cheson, M Narkhede, H Abdel-Razeq, ... Blood 132 (Supplement 1), 140-140, 2018 | 4 | 2018 |
Aziz NazhaLerner College of Medicine/Case Western Reserve UniversityVerified email at ccf.org
